The company has identified several series of CTPS1 inhibitors, with the most advanced series currently undergoing lead optimization.

In November 2017, Step Pharma announced the closing of a Series A financing totalling 14.5 million euros ($16.4 million), with the proceeds to be used to support advancement of first-in-class immunomodulators for autoimmune diseases towards clinical studies.